NCT06872710Not yet recruiting
Prognostic Value of Vitamin D and Intact Parathyroid Hormone (iPTH) in Pulmonary Hypertension
Prognostic Value of Vitamin D and IPTH in Pulmonary Hypertension
Source: ClinicalTrials.gov · Last updated 12 Mar 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The aim of this observational study is to analyse the prognostic value of 25(OH)-vitamin D, iPTH and other serum biomarkers in patients with pulmonary hypertension. Serum samples are obtained from the Spanish Biobank of pulmonary hypertension. Clinical data will be collected from the Spanish registries on pulmonary hypertension (REHAP and REHAR).
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 345 (estimated)
- First submitted
- 3 Mar 2025
- Start date
- 1 Mar 2025
- Primary completion date
- 1 Jul 2025
- Lead sponsor
- Universidad Complutense de Madrid
- NCT number
- NCT06872710
What you commit to
- Study type: Observational
- Planned participants: 345
- From 1 Mar 2025 to the primary completion date, 1 Jul 2025
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Samples from patients that were analyzed in our previous study (PMID: 32041235)
Other illness
- Samples from PAH associated to HIV infection, schistosomiasis or PAH with features of venous/capillary (PVOD/PCH) involvement.
Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.